• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在西非和中非的 HIV 感染者中人类白细胞抗原 HLA-B*57:01 的流行率。

Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa.

机构信息

Laboratoire de Biologie Moléculaire et d'Immunologie (BIOLIM), Université de Lomé, Faculté des Sciences de la santé, Lomé, Togo.

Department of Infectious Diseases, Université Nazi Boni, Bobo-Dioulasso, Burkina Faso.

出版信息

BMC Immunol. 2021 Jul 22;22(1):48. doi: 10.1186/s12865-021-00427-7.

DOI:10.1186/s12865-021-00427-7
PMID:34294032
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8299582/
Abstract

BACKGROUND

The presence of the human leukocyte antigen HLA-B57:01 is associated with the development of a hypersensitivity reaction to abacavir (ABC). Limited data exist on HLA-B57:01 prevalence in individuals with HIV-1 in Africa. This study aimed to estimate HLA-B*57:01 prevalence in individuals with HIV-1 in West and Central Africa.

METHODS

A cross-sectional study was conducted in four countries in West and central Africa (Burkina-Faso, Côte d'Ivoire, Gabon, and Togo) from January 2016 to February 2020 to determine the status of HLA-B57:01 in adults with HIV-1. The presence of HLA-B57:01 was determined by using Single Specific Primer-Polymerase Chain Reaction (SSP-PCR) in blood samples. Prevalence rates were stratified based on country.

RESULTS

A total of 4016 (69.8% women) individuals with HIV were enrolled. Their median age was 45, and the interquartile range was 38-52. We included 500 (12.4%) patients in Burkina-Faso, 1453 (36.2%) in Côte d'Ivoire, 951 (23.7%) in Gabon, and 1112 (27.7%) in Togo. The overall HLA-B57:01 prevalence was 0.1% [95% CI: 0.0-0.2%]. The prevalence of HLA-B57:01 was similar according to the four countries. Only one case was reported in each country except Togo, with no cases.

CONCLUSIONS

HLA-B57:01 prevalence is low in individuals with HIV in West and central Africa, and there is no difference among countries. This study does not confirm the utility of HLA-B57:01 allele testing for abacavir use in this region.

摘要

背景

人类白细胞抗原 HLA-B57:01 的存在与阿巴卡韦（ABC）过敏反应的发生有关。在非洲，HIV-1 感染者中 HLA-B57:01 的流行率数据有限。本研究旨在估计西非和中非 HIV-1 感染者中 HLA-B*57:01 的流行率。

方法

2016 年 1 月至 2020 年 2 月，在西非和中非的四个国家（布基纳法索、科特迪瓦、加蓬和多哥）进行了一项横断面研究，以确定 HIV-1 成人 HLA-B57:01 的状况。采用单特异性引物聚合酶链反应（SSP-PCR）法检测血样中 HLA-B57:01 的存在。根据国家对流行率进行分层。

结果

共纳入 4016 名（69.8%为女性）HIV 感染者。他们的中位年龄为 45 岁，四分位间距为 38-52。我们纳入了 500 名（12.4%）布基纳法索患者、1453 名（36.2%）科特迪瓦患者、951 名（23.7%）加蓬患者和 1112 名（27.7%）多哥患者。总体 HLA-B57:01 流行率为 0.1%[95%CI：0.0-0.2%]。根据四个国家，HLA-B57:01 的流行率相似。除多哥外，每个国家各报告了 1 例病例，多哥没有病例。

结论

西非和中非 HIV 感染者中 HLA-B57:01 的流行率较低，且各国之间无差异。本研究不能证实 HLA-B57:01 等位基因检测在该地区对阿巴卡韦使用的适用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0a6/8299582/2db00e0cecd8/12865_2021_427_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0a6/8299582/2db00e0cecd8/12865_2021_427_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0a6/8299582/2db00e0cecd8/12865_2021_427_Fig1_HTML.jpg

相似文献

1
Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa.在西非和中非的 HIV 感染者中人类白细胞抗原 HLA-B*57:01 的流行率。
BMC Immunol. 2021 Jul 22;22(1):48. doi: 10.1186/s12865-021-00427-7.
2
Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir.尼日利亚接受抗逆转录病毒治疗患者中人类白细胞抗原-B*57:01缺失情况：对阿巴卡韦使用的影响
Niger Postgrad Med J. 2019 Oct-Dec;26(4):195-198. doi: 10.4103/npmj.npmj_75_19.
3
Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.阿根廷HIV-1感染患者中HLA-B*57:01等位基因的流行率
Tissue Antigens. 2015 Jul;86(1):28-31. doi: 10.1111/tan.12575. Epub 2015 Apr 29.
4
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.北美HIV感染受试者中HLA - B*57:01等位基因的流行率以及等位基因检测对HLA - B*57:01阴性受试者中阿巴卡韦相关超敏反应发生率的影响。
BMC Infect Dis. 2017 Apr 11;17(1):256. doi: 10.1186/s12879-017-2331-y.
5
High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia.在塞尔维亚感染 HIV 的患者中人类白细胞抗原-B*57:01 等位基因携带者的高频率。
Intervirology. 2017;60(1-2):43-47. doi: 10.1159/000477810. Epub 2017 Aug 4.
6
Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects.前瞻性流行病学研究人类白细胞抗原 (HLA)-B*5701 在英国 HIV-1 感染者中的流行率。
HIV Med. 2010 Mar;11(3):187-92. doi: 10.1111/j.1468-1293.2009.00762.x. Epub 2009 Sep 24.
7
Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study.在贝宁发生过敏反应的 HIV-1 患者中人类白细胞抗原 HLA-B*57:01 状态：一项初步研究。
BMC Res Notes. 2024 Jul 29;17(1):208. doi: 10.1186/s13104-024-06809-5.
8
HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity.HIV感染的印度儿童中的HLA - B*5701等位基因及其与阿巴卡韦超敏反应的关联
Indian Pediatr. 2018 Feb 15;55(2):140-141. Epub 2017 Dec 14.
9
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.HLA-B*5701、HLA-DR7和HLA-DQ3的存在与对HIV-1逆转录酶抑制剂阿巴卡韦的超敏反应之间的关联。
Lancet. 2002 Mar 2;359(9308):727-32. doi: 10.1016/s0140-6736(02)07873-x.
10
Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.在一大群感染艾滋病毒的患者中，阿巴卡韦不良反应与HLA - B*57:01单倍型的相关性。
Pharmacogenet Genomics. 2020 Oct;30(8):167-174. doi: 10.1097/FPC.0000000000000409.

引用本文的文献

1
Human leucocyte antigen B*57.01 allelic gene is uncommon in Nigerians: An implication for antiretroviral therapy among the HIV/AIDS cohort.人类白细胞抗原B*57.01等位基因在尼日利亚人中并不常见：对艾滋病毒/艾滋病队列抗逆转录病毒治疗的启示。
Indian J Med Res. 2024 May;159(5):530-533. doi: 10.25259/ijmr_1263_23.
2
Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers in People Living with HIV/AIDS in Türkiye.土耳其 HIV/AIDS 感染者中人类白细胞抗原-B*57:01 等位基因携带者的频率。
Curr HIV Res. 2024;22(4):266-269. doi: 10.2174/011570162X316158240801060941.
3
Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study.

本文引用的文献

1
Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir.尼日利亚接受抗逆转录病毒治疗患者中人类白细胞抗原-B*57:01缺失情况：对阿巴卡韦使用的影响
Niger Postgrad Med J. 2019 Oct-Dec;26(4):195-198. doi: 10.4103/npmj.npmj_75_19.
2
HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia.哥伦比亚初治 HIV 感染患者中 HLA-B*57:01 等位基因的流行率。
BMC Infect Dis. 2019 Sep 9;19(1):793. doi: 10.1186/s12879-019-4415-3.
3
Dolutegravir plus abacavir/lamivudine works in adolescents, but size matters.
在贝宁发生过敏反应的 HIV-1 患者中人类白细胞抗原 HLA-B*57:01 状态：一项初步研究。
BMC Res Notes. 2024 Jul 29;17(1):208. doi: 10.1186/s13104-024-06809-5.
4
Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report.严重阿巴卡韦超敏反应患者人类免疫缺陷病毒感染：病例报告。
J Med Case Rep. 2022 Nov 8;16(1):407. doi: 10.1186/s13256-022-03647-6.
5
Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis.阿巴卡韦治疗 HIV 感染婴儿、儿童和青少年的安全性和疗效：系统评价和荟萃分析。
Lancet Child Adolesc Health. 2022 Oct;6(10):692-704. doi: 10.1016/S2352-4642(22)00213-9. Epub 2022 Sep 2.
多替拉韦联合阿巴卡韦/拉米夫定对青少年有效，但剂量很关键。
J Antimicrob Chemother. 2017 Oct 1;72(10):2958-2960. doi: 10.1093/jac/dkx235.
4
Prevalence of HLA-B*5701 in a Kenyan population with HIV infection.肯尼亚HIV感染人群中HLA - B*5701的流行率。
J Infect. 2018 Feb;76(2):212-214. doi: 10.1016/j.jinf.2017.09.007. Epub 2017 Sep 14.
5
Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?简短报告：阿巴卡韦是否应成为撒哈拉以南非洲地区成人艾滋病病毒感染者的一线替代药物？
J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):188-192. doi: 10.1097/QAI.0000000000001487.
6
Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs.降低注射毒品的艾滋病毒感染者中可预防的与艾滋病毒/艾滋病相关的死亡率。
Curr Opin HIV AIDS. 2016 Sep;11(5):507-513. doi: 10.1097/COH.0000000000000297.
7
Low prevalence of human leukocyte antigen-B*5701 in HIV-1-infected Chinese subjects: a prospective epidemiological investigation.中国HIV-1感染人群中人类白细胞抗原-B*5701的低流行率：一项前瞻性流行病学调查
AIDS Res Ther. 2015 Aug 19;12:28. doi: 10.1186/s12981-015-0064-9. eCollection 2015.
8
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.简要报告：多替拉韦联合阿巴卡韦/拉米夫定用于初治HIV-1感染患者的抗逆转录病毒治疗：来自SINGLE随机临床试验的第96周和第144周结果
J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):515-9. doi: 10.1097/QAI.0000000000000790.
9
Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations.多替拉韦-阿巴卡韦-拉米夫定联合用药治疗HIV/AIDS：临床应用及患者考量
Patient Prefer Adherence. 2015 Feb 17;9:299-310. doi: 10.2147/PPA.S65199. eCollection 2015.
10
Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore?在开始阿巴卡韦治疗前进行HLA-B*5701基因分型以降低超敏反应：对临床有用，但在新加坡是否具有成本效益？
Pharmacogenet Genomics. 2015 Feb;25(2):60-72. doi: 10.1097/FPC.0000000000000107.